Companies in brief | Daiichi-Sankyo, Piramal

31 January 2019 - Deborah Wilkes

Daiichi-Sankyo and Piramal have recently released financial results.

Daiichi-Sankyo's OTC sales fall 6.4%

Sales by Daiichi-Sankyo's OTC business in Japan fell by 6.4% to JPY52.9 billion (USD0.48 billion) in the nine months ended 31 December 2018. The Japanese pharmaceutical company highlighted growth of the Minon and Transino brands and said the decrease was mainly due to changes in accounting policy.

The Japanese OTC business accounted for 7.5% of Daiichi-Sankyo's total sales, which decreased by 5.1% to JPY703 billion.

Piramal moves on from GST

Piramal said sales at its India Consumer Products business were INR1.00 billion (USD14.0 million) in the three months ended 31 December 2018. Sales were unchanged compared to the same period a year earlier.

The Indian company pointed out that sales were up by 23% compared to the three months ended 30 September 2018 and by 56% compared to the three months ended 30 June 2018. This indicated "healthy ramping" from the impact of channel destocking around the time of the introduction of the Goods and Services Tax (GST) on 1 July 2017, added the company.

Piramal also noted that India's Fixed Dose Combination (FDC) ban had affected the pain reliever Saridon for a limited period.

However, Piramal obtained a stay order from India's Supreme Court in September 2018 and currently continues to manufacture, sell and distribute Saridon. The company said Saridon Plus had been launched successfully in the Northern and Eastern parts of India.

The India Consumer Products business generated 2.6% of sales at Piramal Enterprises, which were up by 25% to INR95.4 billion in the nine months.

The Indian company has interests in Financial Services, Pharmaceuticals and Healthcare Insights and Analytics.

Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions

Back to Industry News

Share this page: